Company
Inflammatix
Inflammatix is on a bold mission to help bring about a new era in emergency and critical care.
Also known as Inflammatix, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- healthcare providers
- Legal name
- Inflammatix, Inc.
- inflammatix.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Our tests decode the body’s host immune response to reveal new insights, once thought beyond reach, for conditions like pneumonia and sepsis. Just like testing for troponin helped to redefine care for heart attacks, our molecular diagnostics will give healthcare providers the clarity they need to make faster, better decisions. Inflammatix is setting the stage for better patient outcomes and more resilient health systems—building a future where urgent and critical care is as responsive and effective as can be.
Funding snapshot
- Total raised
- $134MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $102M2021-03-15
Funding rounds
- Round, 2021
- $102M2021-03-15, SEC form D sold, 8 investors
- Round, 2020
- $32.1M2020-01-09, SEC form D sold, 6 investors
Products
- Hardware
- Myrna
- Hardware
- TriVerity
Loading relationship preview